Literature DB >> 8985632

Histopathology and molecular cytogenetics of a corneal opacity associated with the trisomy 8 mosaic syndrome (46,XY/47,XY, +8).

J A Scott1, P J Howard, P A Smith, A Fryer, D L Easty, A Patterson, S B Kaye.   

Abstract

The trisomy 8 mosaic syndrome (Tr8MS), karyotype 46,XY/47,XY, +8, is a rare multisystem disorder that may be associated with corneal opacity. We report the case of a dysmorphic infant with multiple congenital abnormalities referred to our unit with a congenital corneal opacity. Subsequent chromosomal analysis of peripheral leucocytes demonstrated constitutional Tr8MS. At 4 years of age, lamellar keratoplasty was performed. Histological examination confirmed the lesion to be consistent with a corneal choristoma. Cytogenetic studies using in situ hybridisation techniques showed the presence of trisomic cells in cell culture derived from the tissue in higher proportion (92%) than in the blood (44%). Amplification of the c-myc oncogene on chromosome-8 could not be detected in cells cultured from the corneal lesion. Although not proof, these findings lend support to the concept of the corneal lesion representing a focus of viable trisomic cells rather than an inflammatory response to a nidus of effete cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985632

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  The association of maternal factors with epibulbar dermoid of newborn: a retrospective, matched case-control study.

Authors:  S Wu; Y Fan; D Wu; J Hong; J Xu
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

Review 2.  Chromosome abnormalities and the genetics of congenital corneal opacification.

Authors:  A Mataftsi; L Islam; D Kelberman; J C Sowden; K K Nischal
Journal:  Mol Vis       Date:  2011-06-17       Impact factor: 2.367

3.  Karyotype changes in cultured human corneal endothelial cells.

Authors:  Takashi Miyai; Yoko Maruyama; Yasuhiro Osakabe; Ryohei Nejima; Kazunori Miyata; Shiro Amano
Journal:  Mol Vis       Date:  2008-05-19       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.